文献速递系统性红斑狼疮其他结缔组织病

基于人群的队列中系统性红斑狼疮的多病共存:Lupus Midwest Network

Multimorbidity in systemic lupus erythematosus in a population-based cohort: the Lupus Midwest Network.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该研究利用基于人群的SLE患病与发病队列及匹配对照,评估57种慢性病。患病队列449例SLE患者多病共存风险约为非SLE对照的3倍(OR 2.98,95%CI 2.18-4.11);发病队列270例新发SLE患者在发病时多病共存风险已高于对照(OR 2.27,95%CI 1.59-3.27),发病后发生多病共存风险为对照的2倍(HR 2.11,95%CI 1.59-2.80)。

要点

  • 患病队列449例SLE患者多病共存风险约为非SLE对照的3倍(OR 2.98,95%CI 2.18-4.11)。
  • 发病队列270例新发SLE患者发病时多病共存风险高于对照(OR 2.27,95%CI 1.59-3.27)。
  • SLE发病后多病共存风险为对照的2倍(HR 2.11,95%CI 1.59-2.80)。

核心结论

  • SLE患者多病共存负担更高,甚至在疾病发病前即已存在。
  • 这种风险差异在SLE分类后持续存在,在患病SLE队列中亦可见。
  • 多病共存既由SDI相关疾病驱动,也由SDI无关疾病驱动。

研究设计与样本

  • 使用基于人群的SLE患病和发病队列及匹配对照,评估57种慢性病。
  • 慢性病分为SDI相关或SDI无关,多病共存定义为存在两种或以上慢性病。
  • 采用逻辑回归比较两队列多病共存患病率,采用Cox模型检查SLE发病后多病共存的发生。

主要发现

  • 患病队列包括449例已确诊SLE患者(2015年1月1日),多病共存风险约为非SLE对照的3倍(OR 2.98,95%CI 2.18-4.11)。
  • 发病队列包括270例新发SLE患者,发病时SLE患者多病共存风险高于对照(OR 2.27,95%CI 1.59-3.27)。
  • 发病后SLE患者发生多病共存风险为对照的2倍(HR 2.11,95%CI 1.59-2.80)。
  • SLE患者多病共存发生基于SDI相关疾病(HR 2.91,95%CI 2.17-3.88)高于基于SDI无关疾病(HR 1.73,95%CI 1.32-2.26)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objectives of this study were to assess the prevalence and incidence of multimorbidity and its association with the SLICC/ACR damage index (SDI) among patients with SLE. METHODS: Using prevalent and incident population-based cohorts of patients with SLE and their matched comparators, we assessed 57 chronic conditions. Chronic conditions were categorized as SDI-related or SDI-unrelated. Multimorbidity was defined as the presence of two or more chronic conditions. The prevalence of multimorbidity for both cohorts was compared using logistic regression. Cox models were used to examine the development of multimorbidity after SLE incidence. RESULTS: The prevalent cohort included 449 patients with established SLE on 1 January 2015. They were three times more likely to have multimorbidity compared with non-SLE comparators [odds ratio (OR) 2.98, 95% CI 2.18-4.11]. The incident cohort included 270 patients with new-onset SLE. At SLE incidence, patients with SLE were more likely to have multimorbidity than comparators (OR 2.27, 95% CI 1.59-3.27). After incidence, the risk of developing multimorbidity was 2-fold higher among patients with SLE than among comparators [hazard ratio (HR) 2.11, 95% CI 1.59-2.80]. The development of multimorbidity was higher in patients with SLE based on SDI-related conditions (HR 2.91, 95% CI 2.17-3.88) than on SDI-unrelated conditions (HR 1.73, 95% CI, 1.32-2.26). CONCLUSION: Patients with SLE had a higher burden of multimorbidity, even before the onset of the disease. The risk disparity continued after SLE classification and was also seen in a prevalent SLE cohort. Multimorbidity was driven both by SDI-related and unrelated conditions.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Figueroa-Parra G, Meade-Aguilar JA, Hulshizer CA, et al. Multimorbidity in systemic lupus erythematosus in a population-based cohort: the Lupus Midwest Network. Rheumatology (Oxford). 2024. PMID: 38001025. doi:10.1093/rheumatology/kead617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。